Benzinga | Mar 24, 2021 07:12AM EDT

BrainStorm Announces Topline Data In Phase 2 Study Evaluating NurOwn As A Treatment For Progressive MS; Study Achieved PRimary Endpoint Of Safety, Improvements Observed In Secondary Endpoints

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline data from the Company's Phase 2 trial evaluating three repeated administrations of NurOwn(r) (MSC-NTF cells), each given 2 months apart, as a treatment for progressive multiple sclerosis (MS). The study achieved the primary endpoint of safety and improvements were observed in secondary endpoints spanning neurologic function, cognition, and biomarkers.